Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China

References

• International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. In: China cancer incidence and mortality 2022. Lyon, France: International Agency for Research on Cancer; 2020 [cited 2024 Apr 11]. https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf
   Google Scholar
• Jim MA, Pinheiro PS, Carreira H, et al. Stomach cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):4994–5013. doi: 10.1002/cncr.30881
   PubMedGoogle Scholar
• Catenacci DVT, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(11):1467–1482. doi: 10.1016/S1470-2045(17)30566-1
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):420–435. doi: 10.1016/S1470-2045(18)30791-5
   PubMed Web of Science ®Google Scholar
• Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–499. doi: 10.1016/S1470-2045(13)70102-5
   PubMed Web of Science ®Google Scholar
• Shah MA, Bang YJ, Lordick F, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-Positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 2017;3(5):620–627. doi: 10.1001/jamaoncol.2016.5580
   PubMed Web of Science ®Google Scholar
• Han G, Sun C, Cui L, et al. Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer. Pathol Oncol Res. 2023;29:1611114. doi: 10.3389/pore.2023.1611114
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45. doi:10.1186/s13045-021-01056-8
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. doi: 10.1016/S0140-6736(21)00797-2
   PubMed Web of Science ®Google Scholar
• Rha SY, Oh DY, Yanez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181–1195. doi: 10.1016/S1470-2045(23)00515-6
   PubMed Web of Science ®Google Scholar
• Xu RH, Oh DY, Kato K, et al. LBA80 tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study. Ann Oncol. 2023;34:S1320–1. doi: 10.1016/j.annonc.2023.10.081
   Google Scholar
• Moehler MH, Kato K, Arkenau H-T, et al. Rationale 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). J Clin Oncol. 2023;41(4_suppl):286. doi: 10.1200/JCO.2023.41.4_suppl.286
   Google Scholar
• Wang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019;11(8):1443–1451. doi: 10.1080/19420862.2019.1654303
   PubMed Web of Science ®Google Scholar
• Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064–2074. doi: 10.1001/jama.2023.19918
   PubMed Web of Science ®Google Scholar
• Xu J, Jiang H, Pan Y, et al. Abstract CT078: First-line treatment with sintilimab (sin) vs placebo in combination with chemotherapy (chemo) in patients (pts) with unresectable gastric or gastroesophageal junction (G/GEJ) cancer: Final overall survival (OS) results from the randomized, phase III ORIENT-16 trial. Cancer Res. 2023;83(8_Supplement):CT078.
   Web of Science ®Google Scholar
• Innovent. Sintilimab approved for first-line treatment of advanced GC/GEJC in combination with chemotherapy 2022 [cited 2023 Oct 21]. Available from: https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=334
   Google Scholar
• Chen Y, Ji X, Xiao H, et al. Impact of the pilot volume-based drug purchasing policy in china: interrupted time-series analysis with controls. Front Pharmacol. 2021;12:804237. doi: 10.3389/fphar.2021.804237
   PubMedGoogle Scholar
• World Health Organization. WHO report on cancer: setting priorities, investing wisely and providing care for all. Geneva (Switzerland): IGO World Health Organization; 2020. Licence: CC BY-NC-SA 3.0.
   Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9. doi: 10.1016/j.jval.2021.11.1351
   PubMed Web of Science ®Google Scholar
• Li W, Wan L, Püsküllüoğlu M. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China. PLOS ONE. 2023;18(6):e0286595. doi:10.1371/journal.pone.0286595
   PubMed Web of Science ®Google Scholar
• Lien K, Cheung MC, Chan KK. Adjusting for drug wastage in economic evaluations of new therapies for hematologic malignancies: a systematic review. J Oncol Pract. 2016;12(4):e369–79. doi:10.1200/JOP.2015.005876
   PubMed Web of Science ®Google Scholar
• Wang FH, Zhang XT, Li YF, et al. The chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (London). 2021;41(8):747–795. doi: 10.1002/cac2.12193
   PubMed Web of Science ®Google Scholar
• Liu GN, Hu SL, Wu JH, et al. China guidelines for pharmacoeconomic evaluation (Chinese-English version). Beijing: China Market Press; 2020.
   Google Scholar
• National Bureau of Statistics. 2023 Statistical bulletin of national economic and social development. [cited 2024 Mar 25]. Available from: https://data.stats.gov.cn/easyquery.htm?cn=C01
   Google Scholar
• Cai D, Shi S, Jiang S, et al. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23(4):607–615. doi: 10.1007/s10198-021-01384-z
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(9). doi: 10.1186/1471-2288-12-9
   PubMedGoogle Scholar
• Li W, Wan L. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China. BMJ Open. 2023;13(9):e074245. doi:10.1136/bmjopen-2023-074245
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE DSU technical support document 21. flexible methods for survival analysis. 2020 [cited 2023 Oct 25]. Available from: https://www.sheffield.ac.uk/sites/default/files/2022-02/TSD21-Flex-Surv-TSD-21_Final_alt_text.pdf
   Google Scholar
• ASCO GI Cancers Symposium. Cancers of the esophagus and stomach and other GI cancers. 2023 [cited 2023 Nov 13]. Available from: https://meetings.asco.org/abstracts-presentations/216281
   Google Scholar
• Yaozh. 2023. [cited 2023 Nov 25]. Available from: https://www.yaozh.com/
   Google Scholar
• Shao T, Zhao M, Liang L, et al. Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug pricing. BioDrugs. 2023;37(3):421–432. doi: 10.1007/s40259-023-00586-6
   PubMed Web of Science ®Google Scholar
• Zhao M, Pan X, Yin Y, et al. Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis. Front Public Health. 2022;10:869960. doi: 10.3389/fpubh.2022.869960
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Wang LXW. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Int J Clin Pharm. 2022;44(2):499–506. doi:10.1007/s11096-021-01372-6
   PubMed Web of Science ®Google Scholar
• Marupuru S, Arku D, Axon DR, et al. Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective. Expert Rev Pharmacoecon Outcomes Res. 2023;23(7):831–841. doi: 10.1080/14737167.2023.2219448
   PubMed Web of Science ®Google Scholar
• Kearns B, Stevenson MD, Triantafyllopoulos K, et al. Generalized linear models for flexible parametric modeling of the hazard function. Med Decis Making. 2019;39(7):867–878. doi: 10.1177/0272989X19873661
   PubMed Web of Science ®Google Scholar
• Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus Bevacizumab vs Sorafenib as first-line treatment of Unresectable Hepatocellular Carcinoma. JAMA Netw Open. 2021;4(2):e210037. doi:10.1001/jamanetworkopen.2021.0037
   PubMed Web of Science ®Google Scholar
• The Chinese Society of Clinical Oncology (CSCO). Guideline for diagnosis and treatment of gastric cancer. 2023 ed. Beijing: People’s Medical Publishing House; 2023.
   Google Scholar
• Lam SW, Wai M, Lau JE, et al. Cost-effectiveness analysis of second-line chemotherapy agents for advanced gastric cancer. Pharmacotherapy. 2017;37(1):94–103. doi: 10.1002/phar.1870
   PubMed Web of Science ®Google Scholar
• Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172–1177. doi: 10.1001/jama.276.14.1172
   PubMed Web of Science ®Google Scholar
• Shu Y, Ding Y, Zhang Q. Cost-effectiveness of nivolumab plus chemotherapy vs. Chemotherapy as first-line treatment for advanced gastric Cancer/Gastroesophageal junction Cancer/Esophagel adenocarcinoma in China. Front Oncol. 2022;12:851522. doi:10.3389/fonc.2022.851522
   PubMed Web of Science ®Google Scholar
• Zhang PF, Shi XQ, Li Q. Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis. Cost Eff Resour Alloc. 2023;21(1):65. doi:10.1186/s12962-023-00476-2
   PubMed Web of Science ®Google Scholar
• National Healthcare Security Administration. National basic medical insurance, work injury insurance and maternity insurance drug catalog. 2022 [cited 2023 Nov 25]. Available from: https://www.gov.cn/zhengce/zhengceku/2023-01/18/5737840/files/5529b4efeb5844aca50abb45c3d74ecf.pdf
   Google Scholar
• Shao T, Zhao M, Tang W. Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma. Front Oncol. 2022;12:953671. doi:10.3389/fonc.2022.953671
   PubMed Web of Science ®Google Scholar
• Morimoto K, Moriwaki K, Shimozuma K, et al. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan. J Gastroenterol. 2023;58(12):1188–1197. doi: 10.1007/s00535-023-02041-3
   PubMed Web of Science ®Google Scholar